Glycogen storage disease type II, also known as Pompe disease, is a rare inherited condition that affects how the body breaks down glycogen, a complex sugar that serves as an energy source. When the enzyme responsible for breaking down glycogen is missing or deficient, this sugar builds up in cells throughout the body, particularly in muscles and the heart, causing progressive weakness and other serious health problems.

Understanding the Disease

Glycogen storage disease type II is a genetic disorder that occurs when the body lacks a specific enzyme called acid alpha-glucosidase, also known as acid maltase. This enzyme normally works inside tiny compartments within cells called lysosomes, which act like recycling centers. The enzyme’s job is to break down glycogen into glucose, a simple sugar that cells use for energy. Without enough of this enzyme, glycogen accumulates in the lysosomes, causing them to swell and damage the cells, especially in muscles throughout the body.^[1]

The disease presents in two main forms that differ significantly in severity and timing. The infantile-onset form is the more severe type, appearing within the first few months of life. The late-onset form can emerge at any age after infancy, including childhood, adolescence, or adulthood, and typically progresses more slowly. The amount of enzyme that remains active in a person’s body plays a major role in determining which form of the disease they develop and how quickly it progresses.^[2]

Epidemiology

Pompe disease is considered rare in the general population. In the United States, approximately 1 in every 40,000 people are affected by this condition. The disease occurs across all ethnic groups, though the frequency can vary among different populations.^[3]

The infantile-onset form represents the classic and most severe presentation of the disease. Before effective treatments became available, infants with this form typically did not survive beyond their first year of life, with the median age at death being approximately 8.7 months. However, this outcome has changed dramatically since enzyme replacement therapy became available, especially when treatment begins early in life.^[2]

The late-onset form can appear at any point from early childhood through adulthood. Because symptoms may be subtle initially and develop gradually, some individuals may not receive a diagnosis until later in life. The progression of late-onset Pompe disease varies considerably from person to person, with some experiencing a relatively mild course while others face more rapid deterioration.^[1]

Causes

The root cause of glycogen storage disease type II lies in mutations of the GAA gene. This gene contains the instructions for producing the acid alpha-glucosidase enzyme. When mutations occur in both copies of this gene, the enzyme cannot function properly or may be absent entirely. As a result, glycogen cannot be broken down effectively inside the lysosomes.^[7]

The disease follows an autosomal recessive pattern of inheritance. This means that a child must inherit one mutated copy of the GAA gene from each parent to develop the condition. Parents who each carry one mutated copy and one normal copy typically do not show any signs or symptoms of the disease themselves—they are simply carriers. When both parents are carriers, each pregnancy carries a 25 percent chance that the child will inherit both mutated genes and develop Pompe disease.^[1]

The specific mutations in the GAA gene determine how much enzyme activity remains. Complete absence of the enzyme or extremely low levels result in the infantile-onset form. When some enzyme activity persists, even if reduced, the late-onset form develops. The retained enzyme activity explains why the late-onset form typically has a milder course and slower progression compared to the infantile form.^[2]

Risk Factors

The primary risk factor for developing Pompe disease is having biological parents who both carry a mutation in the GAA gene. Because the condition is inherited, family history plays the central role in risk. If a couple has already had one child with Pompe disease, there is a one-in-four chance with each subsequent pregnancy that another child will be affected.^[7]

Ethnic background may influence risk to some degree, as certain populations may have higher carrier rates for specific GAA gene mutations. However, Pompe disease has been identified in people of all ethnic backgrounds and geographic regions. Unlike some conditions, lifestyle factors, environmental exposures, or behaviors do not increase or decrease the risk of developing this genetic disorder.^[3]

For couples planning to have children, genetic counseling and carrier testing can help identify whether both partners carry mutations in the GAA gene. This information allows families to understand their risk and make informed decisions about family planning. In some regions, newborn screening programs now test for Pompe disease, allowing for earlier identification and treatment.^[6]

Symptoms

The symptoms of Pompe disease vary dramatically depending on which form a person has and when the disease begins. In the infantile-onset form, symptoms typically appear within the first few months of life, often around four to eight months of age. Babies with this form usually present with severe muscle weakness and poor muscle tone, often described as “floppy baby” syndrome or hypotonia. They may be unable to hold up their heads or achieve other motor milestones expected for their age, such as rolling over or sitting up.^[2]

Infants with the disease often develop an enlarged heart, a condition called cardiomegaly, along with thickening of the heart muscle known as hypertrophic cardiomyopathy. This affects the heart’s ability to pump blood effectively, potentially leading to heart failure. Breathing muscles become progressively weaker, causing respiratory distress and difficulty breathing. Affected infants may also have trouble feeding, fail to gain weight at the expected rate, and experience developmental delays. The liver may become enlarged, and the tongue can appear unusually large, a condition called macroglossia. Some infants also develop hearing problems.^[1]

The late-onset form presents differently, with symptoms that may be milder and develop more gradually over time. The hallmark symptom is progressive muscle weakness, particularly affecting the large muscles of the legs, trunk, arms, and shoulders. This weakness makes activities like walking, climbing stairs, and lifting objects increasingly difficult. Over time, the muscles involved in breathing, especially the diaphragm, become affected, leading to respiratory insufficiency.^[3]

People with late-onset Pompe disease may first notice difficulty with nighttime breathing or wake up feeling unrested. They might experience shortness of breath, especially during physical activity or when lying flat. Some individuals develop widespread muscle pain. Unlike the infantile form, heart problems are rare in late-onset Pompe disease, though occasional heart rhythm abnormalities or mild heart muscle thickening can occur. As the disease progresses, some people may require assistive devices for mobility, such as wheelchairs, and eventually need breathing support with devices like BiPAP machines or ventilators.^[5]

Prevention

Because Pompe disease is an inherited genetic condition caused by mutations present from birth, there is no way to prevent the disease itself from developing in someone who inherits the mutations from both parents. However, several approaches can help identify risk and enable early intervention, which significantly improves outcomes.^[7]

For families with a history of Pompe disease or known carrier status, genetic counseling provides valuable information about inheritance risks. Couples who are both carriers can explore options including preimplantation genetic diagnosis, where embryos created through in vitro fertilization are tested for the mutations before implantation. Prenatal testing through procedures like amniocentesis or chorionic villus sampling can determine whether a developing fetus has inherited the condition.^[1]

Newborn screening programs have become increasingly important in the early detection of Pompe disease. Many regions now include testing for reduced acid alpha-glucosidase enzyme levels as part of routine newborn screening performed shortly after birth. When the screening identifies low enzyme levels, follow-up testing confirms whether the baby has Pompe disease. Early detection through newborn screening allows treatment to begin before severe symptoms develop, which can dramatically improve long-term outcomes, particularly for infants with the severe early-onset form.^[6]

While treatment cannot cure the disease, starting enzyme replacement therapy early, especially before significant organ damage occurs, helps maintain better muscle strength, prevents or reduces heart enlargement, and improves survival. For this reason, prompt identification through screening and immediate initiation of treatment serve as the most effective strategy for preventing the most severe complications and early death associated with Pompe disease.^[1]

Pathophysiology

The pathophysiology of glycogen storage disease type II centers on the malfunction of cellular recycling systems. Normally, cells continuously break down and recycle their components through lysosomes, which contain various enzymes designed to degrade different substances. The acid alpha-glucosidase enzyme specifically breaks down glycogen that enters these lysosomes. When this enzyme is deficient or absent, glycogen cannot be properly degraded and begins to accumulate within the lysosomes.^[2]

As glycogen builds up, the lysosomes become progressively enlarged and filled with unprocessed material. This lysosomal expansion disrupts the normal structure and function of cells. Muscle cells are particularly vulnerable to this damage because they normally contain higher amounts of glycogen for quick energy access during physical activity. The accumulation damages muscle fibers, causing them to progressively weaken and eventually die. This cellular damage manifests as the muscle weakness and wasting that characterize the disease.^[1]

In the infantile form, where enzyme activity is virtually absent, glycogen accumulation occurs rapidly and extensively. The heart muscle, which works constantly and requires significant energy, accumulates large amounts of glycogen, leading to thickening and enlargement. This interferes with the heart’s ability to contract effectively and pump blood. The respiratory muscles, including the diaphragm and chest wall muscles, also accumulate glycogen, progressively weakening and making breathing increasingly difficult.^[3]

In the late-onset form, some residual enzyme activity persists, allowing partial glycogen breakdown. This results in slower accumulation and less severe damage initially. Over time, however, the continued buildup still causes progressive muscle damage. The skeletal muscles of the limbs and trunk gradually weaken, and eventually, the diaphragm and other breathing muscles become affected. Because more enzyme activity remains in late-onset disease, the heart typically escapes significant damage, explaining why cardiac problems are rare in this form.^[5]

The glycogen accumulation also affects other tissues to varying degrees. The liver may become enlarged as glycogen builds up in liver cells, though liver function typically remains adequate. The nervous system can be affected, particularly in severe infantile cases, where glycogen deposits may accumulate in nerve cells. The tongue muscle may become infiltrated with glycogen, causing enlargement. The widespread nature of this cellular dysfunction explains why Pompe disease affects multiple organ systems and requires comprehensive medical management.^[2]

An important factor in infantile-onset disease is cross-reactive immunologic material (CRIM) status. Patients who produce no GAA protein at all are classified as CRIM-negative. When these patients receive enzyme replacement therapy, their immune systems may recognize the infused enzyme as completely foreign and mount a strong antibody response against it, reducing treatment effectiveness. CRIM-positive patients, who produce some non-functional or poorly functional enzyme, are less likely to develop high antibody levels because their immune systems have been exposed to the GAA protein. This immunologic factor significantly influences treatment response and long-term outcomes.^[2]